Published on December 3, 2009 at 2:16 AM
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 11,500,000 shares of its common stock in an underwritten offering at a price to the public of $38.50 per share, which would result in aggregate gross proceeds of $442.8 million. Vertex has granted the underwriters an option to purchase up to an additional 1,500,000 shares of its common stock on the same terms and conditions.
Goldman, Sachs & Co. is acting as the sole book-running manager for the offering, with BofA Merrill Lynch, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated acting as co-managers.
Source: Vertex Pharmaceuticals Incorporated